RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)

Korábbi kezelés

• According to the investigator's opinion, the patient is an unlikely candidate to provide an accurate medical history and/or to obtain long-term follow-up information for any reasons such as unavailability or severe concomitant illnesses.

Egyéb

• Patients meeting ANY of the following criteria are not eligible for participation:
• Asciminib based treatment regimen in first or second line.
• Patients are currently participating in any other clinical trials.
• Patients who refused to sign informed consent.

• Patients eligible for inclusion in this study must meet all the following criteria:
• Signed and dated Patient Informed Consent Form obtained.
• Male or female patients with a diagnosis of Ph+ CML-CP ≥18 years of age with the following laboratory values:
  • <15% blasts in peripheral blood and bone marrow
  • <30% blasts plus promyelocytes in peripheral blood and bone marrow
  • <20% basophils in the peripheral blood
  • ≥50 x 109/L (≥50,000/mm3) platelets
• Prior treatment with a minimum of 2 prior TKIs: e. First-generation TKI imatinib f. 2G-TKI dasatinib, nilotinib and bosutinib g. 3G-TKI ponatinib 4. Patients are currently receiving asciminib as per approved local label and independently of study participation. Patients must have started asciminib therapy no more than 6 months prior to their enrollment in the study.